Tandem Diabetes Care Acquires Capillary Biomedical

Abbott Acquires Bigfoot Biomedical

September 5, 2023

Medical Devices

Abbott has entered a definitive agreement to acquire Bigfoot Biomedical, a developer of smart insulin management systems that integrate continuous glucose monitoring with connected insulin pen caps and a cloud-based provider portal. The acquisition will combine Abbott’s FreeStyle Libre CGM technology with Bigfoot’s dosing-capable pen cap platform to further develop personalized, connected diabetes care solutions; the deal is expected to close in Q3 2023 and financial terms were not disclosed.

Tandem Diabetes Care Acquires Sugarmate

June 24, 2020

Software

Tandem Diabetes Care acquired Sugarmate, a diabetes-focused mobile app, with Sugarmate becoming a wholly owned subsidiary and its founder Josh Juster joining Tandem as Vice President, Sugarmate. The acquisition strengthens Tandem's digital health offerings and expands its ecosystem of diabetes-related products and services; financial terms were not disclosed.

MTD Group Acquires Ypsomed's Pen Needles and Blood Glucose Monitoring Businesses

August 2, 2024

Medical Devices

MTD Group (Medical Technology and Devices) has completed the acquisition of Ypsomed’s pen needles and blood glucose monitoring systems businesses. The deal expands MTD’s diabetes and obesity care portfolio, increases European production capacity to over 2.5 billion pen needles, and provides entry into high-growth markets including China and India while prompting a significant investment plan for European production sites.

Capillary Technologies Acquires Brierley+Partners

April 4, 2023

Marketing & Advertising

Capillary Technologies, a Bengaluru-based customer loyalty SaaS platform, has acquired Texas-headquartered Brierley+Partners to strengthen its presence in the United States and expand its loyalty services and capabilities. The purchase brings Brierley's 30+ years of loyalty strategy, program design and execution expertise into Capillary's AI-powered platform, accelerating product capabilities and go-to-market reach for enterprise clients.

TandemAI Merges with Perpetual Medicines to Expand Peptide and AI Drug Discovery Capabilities

July 10, 2025

Biotechnology

TandemAI and Perpetual Medicines have merged, with the combined company operating under the TandemAI name. Perpetual Medicines will operate as a separate entity within TandemAI to extend the firm's capabilities into computational peptide design and integrated synthesis, while leadership from both companies will continue in senior roles; financial terms were not disclosed.

Capillary Technologies Acquires Kognitiv

May 14, 2025

Marketing & Advertising

Capillary Technologies, an AI-powered loyalty management company headquartered in Bengaluru, has acquired Kognitiv, a Toronto-based provider of omnichannel loyalty solutions. The acquisition expands Capillary's enterprise client portfolio and strengthens its presence across North America, ANZ, Southeast Asia and the UAE while enhancing its data-driven personalization and loyalty capabilities.